Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis
Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Tomás Pascual(Breast Cancer Research Foundation), Lorea Villanueva, Fernando Salvador(Solti), Eva Ciruelos(Hospital Universitario 12 De Octubre), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Rodrigo Dienstmann(Universitat de Vic - Universitat Central de Catalunya), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre)
Cited by 30
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
|Nature reviews. Cancer|2017|1k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684